Class I and/or III antiarrhythmics vs control
Adverse events: thromboembolic events · Human trial participants undergoing ablation for atrial fibrillation
It is very uncertain whether class I and/or III antiarrhythmics changes adverse events: thromboembolic events compared with control (very low certainty).
1 finding from 1 review
- Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes onlyPeto OR 0.96 [0.06, 15.5]1 study · 212 participantsVery low